A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study

Zhang, Ran; Cui, Yanxin; Guan, Xin; Jiang, Xiangjun

doi:10.3389/fonc.2021.752504

Cited by 13 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…What also was noted, is that side effects typical for chemotherapy such as nausea, vomiting, granulocytopenia, anemia, and hair loss occurred in patients from groups B and C (with no statistically significant difference between them) and more commonly than in group A. Pyrexia was observed mostly in patients from groups A and B. The study showed that Oncorine may be a therapeutic option for patients with gastric carcinoma in combination with chemotherapy ( 66 ). In 2022 the next retrospective study was carried out on the efficacy and safety of Oncorine in 29 patients with persistent, recurrent, or metastatic gynecologic malignancies: cervical cancer (22 cases), vaginal cancer (2 cases), vulvar cancer (3 cases) and ovarian cancer (2 cases).…”

Section: Discussionmentioning

confidence: 80%

New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy

Chowaniec,

Ślubowska,

Mroczek

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Oncolytic virus (OV) therapy has emerged as a promising frontier in cancer treatment, especially for solid tumours. While immunotherapies like immune checkpoint inhibitors and CAR-T cells have demonstrated impressive results, their limitations in inducing complete tumour regression have spurred researchers to explore new approaches targeting tumours resistant to current immunotherapies. OVs, both natural and genetically engineered, selectively replicate within cancer cells, inducing their lysis while sparing normal tissues. Recent advancements in clinical research and genetic engineering have enabled the development of targeted viruses that modify the tumour microenvironment, triggering anti-tumour immune responses and exhibiting synergistic effects with other cancer therapies. Several OVs have been studied for breast cancer treatment, including adenovirus, protoparvovirus, vaccinia virus, reovirus, and herpes simplex virus type I (HSV-1). These viruses have been modified or engineered to enhance their tumour-selective replication, reduce toxicity, and improve oncolytic properties.Newer generations of OVs, such as Oncoviron and Delta-24-RGD adenovirus, exhibit heightened replication selectivity and enhanced anticancer effects, particularly in breast cancer models. Clinical trials have explored the efficacy and safety of various OVs in treating different cancers, including melanoma, nasopharyngeal carcinoma, head and neck cancer, and gynecologic malignancies. Notably, Talimogene laherparepvec (T-VEC) and Oncorine have. been approved for advanced melanoma and nasopharyngeal carcinoma, respectively. However, adverse effects have been reported in some cases, including flu-like symptoms and rare instances of severe complications such as fistula formation. Although no OV has been approved specifically for breast cancer treatment, ongoing preclinical clinical trials focus on four groups of viruses. While mild adverse effects like low-grade fever and nausea have been observed, the effectiveness of OV monotherapy in breast cancer remains insufficient. Combination strategies integrating OVs with chemotherapy, radiotherapy, or immunotherapy, show promise in improving therapeutic outcomes. Oncolytic virus therapy holds substantial potential in breast cancer treatment, demonstrating safety in trials. Multi-approach strategies combining OVs with conventional therapies exhibit more promising therapeutic effects than monotherapy, signalling a hopeful future for OV-based breast cancer treatments.

show abstract

Section: Discussionmentioning

confidence: 80%

New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy

Chowaniec,

Ślubowska,

Mroczek

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The first FDA- and European Medicines Agency-approved oncolytic virus, talimogene laherparepvec (T-VEC), is a modified HSV virus for the treatment of malignant melanoma that encodes GM-CSF to enhance antitumor immune responses ( 150 ). A recombinant adenovirus (Oncorine ® ) was approved by Chinese regulators as early as November 2005 for the treatment of HNC (in combination with chemotherapy) and a number of oncolytic viruses are in clinical development ( 151 , 152 ). The multifunctional properties of oncolytic viruses in tumor therapy make them highly synergistic when used in combination with other drugs ( 153 ).…”

Section: Future Immunotherapymentioning

confidence: 99%

Immunotherapy: A new target for cancer cure (Review)

et al. 2023

View full text Add to dashboard Cite

Cancer is the leading cause of death globally and there is a worldwide cancer epidemic. Immunotherapy has emerged as a promising anticancer therapy. In particular, oncolytic viruses destroy cancer cells without destroying normal tissue via viral self-replication and anti-tumor immune responses, showing potential for cancer therapy. The present review discusses the role of the immune system in the treatment of tumor. The strategies for treating tumors are briefly introduced from aspects of active immunization and passive immunotherapy and the dendritic cell vaccines and oncolytic viruses are highlighted, as well as use of blood group A antigen in the treatment of solid tumors.

show abstract

“…Others have also shown that tumor selectivity can also be achieved by the deletion of E1B-19 kDa ( Liu et al, 2004 ). Another oAdV, H101, is similar to ONYX-015 except it carries a mutation in the E3 gene region which is associated with immune evasion ( Zhang et al, 2021 ). H101 was well tolerated and demonstrated anti-tumoral activity in patients ( Lu et al, 2004 ).…”

Section: Different Oncolytic Viruses Applied As Immunotherapeutic Age...mentioning

confidence: 99%

Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy

et al. 2022

View full text Add to dashboard Cite

The worldwide burden of cancers is increasing at a very high rate, including the aggressive and resistant forms of cancers. Certain levels of breakthrough have been achieved with the conventional treatment methods being used to treat different forms of cancers, but with some limitations. These limitations include hazardous side effects, destruction of non-tumor healthy cells that are rapidly dividing and developing, tumor resistance to anti-cancer drugs, damage to tissues and organs, and so on. However, oncolytic viruses have emerged as a worthwhile immunotherapeutic option for the treatment of different types of cancers. In this treatment approach, oncolytic viruses are being modeled to target cancer cells with optimum cytotoxicity and spare normal cells with optimal safety, without the oncolytic viruses themselves being killed by the host immune defense system. Oncolytic viral infection of the cancer cells are also being genetically manipulated (either by removal or addition of certain genes into the oncolytic virus genome) to make the tumor more visible and available for attack by the host immune cells. Hence, different variants of these viruses are being developed to optimize their antitumor effects. In this review, we examined how grave the burden of cancer is on a global level, particularly in sub-Saharan Africa, major conventional therapeutic approaches to the treatment of cancer and their individual drawbacks. We discussed the mechanisms of action employed by these oncolytic viruses and different viruses that have found their relevance in the fight against various forms of cancers. Some pre-clinical and clinical trials that involve oncolytic viruses in cancer management were reported. This review also examined the toxicity and safety concerns surrounding the adoption of oncolytic viro-immunotherapy for the treatment of cancers and the likely future directions for researchers and general audience who wants updated information.

show abstract

A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study

Cited by 13 publications

References 34 publications

New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy

New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy

Immunotherapy: A new target for cancer cure (Review)

Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy

Contact Info

Product

Resources

About